Newtopia Completes $2 Million Debt Financing, Assignment of Existing Senior Secured Credit Facility and Provides Corporate Update
Summary
""Now, on the strength of this new financing, Newtopia will leverage our core capabilities and strengths to drive even greater value to stakeholders by combining our proven habit change platform with GLP-1 drugs for obesity and type 2 diabetes management, and by partnering with health AI and clinical discovery innovators to improve our collective ability to prevent, reverse and slow chronic disease," Ruby added.Ruby concluded, "Newtopia has spent the past 12 years partnering with the most sophisticated market innovators to deliver proven habit change solutions that are sustainable and affordable. These core competencies, together with our unparalleled experience, are now wonderfully complementary to the remarkable GLP-1 class of drugs that require engaging and effective habit change to sustain their positive outcomes and deliver a return on investment over time. Newtopia stands in a unique position to enable this progress, given our attractive value-based unit economics, our tech-enabled and scalable offering, and our current, cash flow break-even operating mode. There can be no assurance that the FFCTO will be revoked on the timeline contemplated by the Company.Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse metabolic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders.